Asklepios Medical School Hamburg, Semmelweis University, Budapest, Hungary.
Department of Cardiology and Internal Intensive Care Medicine, Asklepios Hospital St. Georg, Hamburg, Germany.
Oncol Res Treat. 2023;46(5):201-210. doi: 10.1159/000529788. Epub 2023 Feb 23.
SARS-CoV-2 infected patients with cancer have a worse outcome including a significant higher mortality, compared to non-cancer patients. However, limited data are available regarding in-hospital mortality during the Omicron phase of the pandemic. Therefore, the aim of the study was the comparison of mortality in patients with history of cancer and patients with active cancer disease during the different phases of the COVID-19 pandemic, focusing on the current Omicron variant of concern.
We conducted a multicenter, observational, epidemiological cohort study at 45 hospitals in Germany. Until July 20, 2022, all adult hospitalized SARS-CoV-2 positive patients were included. The primary endpoint was in-hospital mortality regarding cancer status (history of cancer and active cancer disease) and SARS-CoV-2 virus type.
From March 11, 2020, to July 20, 2022, a total of 27,490 adult SARS-CoV-2 positive patients were included in the study. 2,578 patients (9.4%) had diagnosis of cancer, of whom 1,065 (41.3%) had history of cancer, whereas 1,513 (58.7%) had active cancer disease. Overall 3,749 out of the total of 27,490 patients (13.6%) died during the hospital stay. Patients with active cancer disease had a significantly higher mortality compared to patients without cancer diagnosis, in both phases of the pandemic (wild-type to Delta: OR 1.940 [1.646-2.285]); Omicron: 2.864 [2.354-3.486]). After adjustment to co-variables, SARS-CoV-2 infected patients with active cancer disease had the highest risk for in-hospital mortality compared to the other groups, in both phases of the pandemic.
The CORONA Germany study indicates that hospitalized patients with active cancer disease are at high risk of death during a SARS-CoV-2 infection. Mortality of patients with history of cancer improved to nearly the level of non-cancer patients during Omicron phase.
与非癌症患者相比，感染 SARS-CoV-2 的癌症患者预后更差，包括死亡率显著升高。然而，关于大流行奥密克戎阶段住院患者的死亡率数据有限。因此，本研究旨在比较 COVID-19 大流行不同阶段癌症史患者和活动性癌症患者的死亡率，重点关注当前关注的奥密克戎变体。
我们在德国的 45 家医院进行了一项多中心、观察性、流行病学队列研究。截至 2022 年 7 月 20 日，纳入所有成年住院 SARS-CoV-2 阳性患者。主要终点是癌症状态（癌症史和活动性癌症疾病）和 SARS-CoV-2 病毒类型的住院死亡率。
从 2020 年 3 月 11 日至 2022 年 7 月 20 日，共纳入 27490 名成年 SARS-CoV-2 阳性患者。2578 名患者（9.4%）诊断患有癌症，其中 1065 名（41.3%）有癌症史，1513 名（58.7%）有活动性癌症疾病。在总住院人数 27490 人中，共有 3749 人（13.6%）在住院期间死亡。在大流行的两个阶段（野生型到德尔塔：OR 1.940 [1.646-2.285]）和奥密克戎阶段（2.864 [2.354-3.486]），活动性癌症患者的死亡率均明显高于无癌症诊断的患者。调整协变量后，在大流行的两个阶段，与其他组相比，感染 SARS-CoV-2 的活动性癌症患者的住院死亡率风险最高。
德国 CORONA 研究表明，患有活动性癌症的住院患者在 SARS-CoV-2 感染期间死亡风险高。奥密克戎阶段癌症史患者的死亡率已接近非癌症患者的水平。
